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EphA2, a member of the Eph receptor tyrosine kinases, is frequently 
overexpressed in a variety of malignancies, including glioblastoma, and its 
expression is correlated with poor prognosis. EphA2 acts as a tumor 
promoter through a ligand ephrin-independent mechanism, which requires 
phosphorylation of EphA2 on serine 897 (S897), leading to increased cell 
migration and invasion. In this study, we show that ligand-independent 
EphA2 signaling occurs downstream of the MEK/ERK/RSK pathway and 
mediates epidermal growth factor (EGF)-induced cell proliferation in 
glioblastoma cells. Suppression of EphA2 expression by long-term 
exposure to ligand ephrinA1 or EphA2-targeted shRNA inhibited 
EGF-induced cell proliferation. Stimulation of the cells with EGF induced 
EphA2 S897 phosphorylation, which was suppressed by MEK and RSK 
inhibitors, but not by phosphatidylinositol 3-kinase (PI3K) and Akt 
inhibitors. The RSK inhibitor or RSK2-targeted shRNA also suppressed 
EGF-induced cell proliferation. Furthermore, overexpression of wild-type 
EphA2 promoted cell proliferation without EGF stimulation, whereas 
overexpression of EphA2-S897A mutant suppressed EGF- or 
RSK2-induced proliferation. Taken together, these results suggest that 
EphA2 is a key downstream target of the MEK/ERK/RSK signaling 
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pathway in the regulation of glioblastoma cell proliferation.   
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1. Introduction 
Glioblastoma is the most frequent malignant brain tumor, and is also 
one of the most lethal human cancers. Signaling from receptor tyrosine 
kinases is known to play key roles in regulating cell proliferation, survival, 
migration, and metabolism, and amplification and mutations of those 
kinases are major factors in development and progression of glioblastoma. 
Among them, epidermal growth factor (EGF) receptor is the most 
frequently mutated genes in glioblastoma [1, 2]. EGF receptor mutations 
and amplification alter the activities of downstream signaling pathways, 
including the Ras/Raf/MEK/ERK pathway and the PI3K/Akt signaling 
pathway, both of which contribute to the regulation of cell proliferation, 
survival, and motility [3].  
The p90 ribosomal S6 kinase (RSK) family of serine/threonine 
protein kinases is directly activated by ERK1 and ERK2 downstream of 
tyrosine kinase receptors including EGF receptor. In human, four RSK 
isoforms (RSK1-4) have been identified, and their unique structural 
features are the presence of two distinct functional kinase domains. They 
share a high degree of sequence homology, especially in the two kinase 
domains [4-6]. RSKs are implicated in a variety of cellular functions, 
including cell proliferation and migration, through phosphorylation of 
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various cytosolic and nuclear targets. RSKs are also involved in the 
regulation of cancer cell proliferation and invasion, and emerge as potential 
therapeutic targets in various types of human cancer [5-7]. In glioblastoma, 
a marked increase of RSK2 expression in patient samples compared to that 
in normal brain tissues was observed [8], although its role in glioblastoma 
cells is not fully understood. 
Eph receptors constitute the largest family of receptor tyrosine 
kinases. Their ligands, ephrins, are membrane-anchored proteins, and 
ephrin-Eph receptor interactions caused by cell-cell contact initiate tyrosine 
phosphorylation and signaling of Eph receptors via homotypic Eph-Eph 
interactions and regulate cell proliferation and migration during 
development and in tissue homeostasis [9-10]. Many studies have shown 
that dysregulation of ephrin/Eph receptor signaling contributes to cancer 
progression. Among them, EphA2 is frequently overexpressed in a variety 
of human cancers including glioblastoma [11-13]. EphA2 is highly 
expressed in specimens of glioblastoma but not in normal brain, and 
increased expression of EphA2 has been shown to correlate with poor 
survival of patients with glioblastoma [14-16]. Previous studies have 
reported that EphA2 mediates ligand ephrin-independent promotion of cell 
migration and invasion, whereas stimulation of EphA2 with ligand 
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ephrinA1 suppresses cell migration [17-21]. EphA2 has been also shown to 
contribute to the maintenance of stem-like tumor-propagating cells in 
glioblastoma [22, 23]. Phosphorylation of EphA2 on serine 897 (S897) by 
Akt plays a key role in EphA2 ligand-independent signaling. In contrast, 
ligand ephrinA1 stimulation induces dephosphorylation of EphA2 on S897 
and suppresses EphA2 ligand-independent effects [17, 24]. However, a 
recent study reported that RSK phosphorylates S897 of EphA2 in various 
cancer cell types and promotes cell migration and invasion [25]. In the 
present study, we provide evidence that EGF induces phosphorylation of 
EphA2 on S897 through the MEK/ERK/RSK pathway and promotes 
glioblastoma cell proliferation. Our results suggest that EphA2 serves as a 
key RSK substrate for the regulation of glioblastoma cell proliferation and 
cancer progression.      
 
2. Materials and Methods 
2.1. Plasmids 
Wild-type EphA2 (EphA2-WT) and S897A mutant (EphA2-SA) 
were subcloned into pcDNA3 vector (Life Technologies) as described 
previously [21, 24]. The YFP expression vector (pCAG) [26] was a 
generous gift from Drs. J. Miyazaki (Osaka University, Osaka, Japan) and T. 
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Saito (Chiba University, Chiba, Japan). Human RSK2 was obtained from 
U-251 cells and subcloned into pcDNA3 with a HA tag sequence at the 
N-terminus. The nucleotide sequence was confirmed after construction 
using the ABI Prism 310 Genetic Analyzer. We used a double promoter 
vector, encoding YFP and a short hairpin RNA (shRNA) for control 
luciferase (shControl) or EphA2 (shEphA2) to express YFP protein and the 
shRNA in the same cells, as described previously [27]. The shRNA for 
human RSK2 was designed to target 21 nucleotides of the human RSK2 
transcript (5’-gggaggagatttgtttacacg-3’ [25]) and expressed using 
pSilencer-hygro (Life Technologies). 
 
2.2. Reagents and Antibodies  
 The pharmacological MEK inhibitors U0126 and PD98059, and 
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 were purchased 
from Merck Millipore. Akt inhibitor MK-2206 was from ChemieTek, and 
RSK inhibitor BI-D1870 was from Santa Cruz Biotechnology. We used the 
following antibodies in this study: a rabbit polyclonal antibody against 
EphA2 (C-20) (Santa Cruz Biotechnology); a mouse monoclonal antibody 
against a-tubulin (Sigma); rabbit monoclonal antibodies against S897 
phospho-EphA2 (D9A1) and T308 phospho-Akt (C31E5E), rabbit 
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polyclonal antibodies against Akt, ERK, and T202/Y204 phospho-ERK, a 
mouse monoclonal antibody against EphA2 (8B6) (Cell Signaling 
Technology); a mouse monoclonal antibody against HA (3F10) (Millipore); 
secondary antibodies conjugated to horseradish peroxidase (DAKO); Alexa 
Fluor 488-conjugated anti-GFP and Alexa Fluor 594-conjugated goat 
anti-mouse IgG (Thermo Fisher Scientific). 
  
2.3. Cell culture and transfection 
U-251 cell line was obtained from European Collection of Cell 
Cultures (ECACC). A172 cell line was provided by the RIKEN BRC 
through the National Bio-Resource Project of the MEXT, Japan. U-251, 
A172, and HEK293T cells were grown in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum, 4 mM glutamine, 100 units/ml 
of penicillin, and 0.1 mg/ml of streptomycin under humidified air 
containing 5% CO2 at 37ºC. Cells were transfected with indicated 
expression vectors using polyethyleneimine MAX.  
 
2.4. MTT assay 
Cell proliferation was assessed using the 3-(4, 
5-dimethyl-2-thiazolyl)-2, 5-diphenyltetrazolium bromide (MTT) assay. 
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U-251 cells were seeded onto 96-well plates (2500 cells/well) in serum-free 
medium for 15 h. Then cells were treated with 100 ng/ml recombinant 
human EGF (Sigma) together with 1 µg/ml control human Fc (Jackson 
ImmunoResearch Laboratories) or ephrinA1-Fc (R&D Systems) and 
cultured for 48 h. MTT (5 mg/ml in PBS) was added to each well, and the 
wells were incubated for 4 h. The purple-blue MTT formazan precipitate 
was dissolved in isopropanol containing 0.04N HCl. The optical density 
was measured at 595 nm using a microplate reader (Tecan).  
 
2.5. Bromodeoxyuridine (BrdU) incorporation and TUNEL assay 
U-251 and A172 cells cultured on coverslips were treated with BrdU 
(10 µM) for 30 min (U-251 cells) or 6 h (A172 cells) and fixed with 4% 
paraformaldehyde in PBS for 20 min at room temperature. To identify 
BrdU-incorporated cells, cells were pretreated with 4N HCl in PBS for 5 
min at room temperature. Cells were then incubated with 0.2% Triton 
X-100 in PBS for 10 min and with 10% fetal bovine serum in PBS for 30 
min to block nonspecific antibody binding. Cells were incubated with 
anti-BrdU antibody in PBS overnight at 4 °C, followed by incubation with 
Alexa Fluor 594-conjugated anti-mouse IgG antibody together with Alexa 
Fluor 488-conjugated anti-GFP antibody or Hochst 33258 (Thermo Fisher 
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Scientific) for 1 h at room temperature. After washing with PBS, cells were 
mounted in 90% glycerol containing 0.1% p-phenylenediamine 
dihydrochloride in PBS. Apoptotic cell death was detected by TUNEL 
(Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) 
assay using in situ cell death detection kit, TMR red (Roche) according to 
the manufacture’s instruction. As a positive control, U-251 cells were 
treated with 1 mM H2O2 for 24 h [28]. Images were acquired using a Nikon 
Eclipse E800 microscope equipped with a 20x objective and a digital 
camera (Leica DC350F).  
 
2.6. Immunoblotting 
Cell lysates were separated by SDS-PAGE and electrophoretically 
transferred onto a polyvinylidene difluoride membrane (Millipore 
Corporation). The membrane was blocked with 3% low fat milk in 
Tris-buffered saline, and then incubated with primary antibodies. The 
primary antibodies were detected with horseradish peroxidase-conjugated 
secondary antibodies and enhanced chemiluminescence (ECL) detection kit 
(GE Healthcare).  
 
2.7. Data analysis 
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Statistical significance was established using the two-sample 
Student’s t test or the analysis of variance (ANOVA) and post hoc test 




3.1. EphA2 is involved in EGF-induced cell proliferation in glioblastoma 
cells 
To investigate whether EphA2 plays a role in EGF-triggered cell 
proliferation in glioblastoma, we used the glioblastoma cell line U-251. As 
reported previously in other cells [22, 29], expression of EphA2 in U-251 
cells was down-regulated after long exposure (24 and 48 h) to ephrinA1-Fc 
(Fig. 1A). We found that long exposure to ephrinA1-Fc reduced the number 
of U-251 cells at 48 h after stimulation with EGF (Fig. 1B). We quantified 
cell proliferation by MTT assay, and found that treatment of U-251 cells 
with ephrinA1-Fc (48 h) significantly suppressed EGF-induced cell 
proliferation compared to control-Fc treatment (Fig. 1C). Previous studies 
have reported that ephrinA1-EphA2 interaction or EphA2 silencing can 
induce apoptosis [30, 31]. However, we could not detect apoptotic cells 
within 48 h after treatment of U-251 cells with ephrinA1-Fc (Fig. 1D, H2O2 
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was used as a positive control [28]). We further examined the effect of long 
exposure to ephrinA1 on EGF-stimulated cell proliferation by BrdU 
incorporation. After U-251 cells were stimulated with EGF in the presence 
of ephrinA1-Fc or control Fc for 20 h, they were labeled with BrdU for 30 
min followed by staining with anti-BrdU antibody. Stimulation of U-251 
cells with EGF increased the number of BrdU-positive cells. However, 
ephrinA1 treatment significantly suppressed EGF-induced BrdU 
incoporation (Fig. 2A and B). To confirm the involvement of EphA2 in 
EGF-stimulated U-251 cell proliferation, cells were transfected with 
shRNA against human EphA2 (shEphA2) or control shRNA (shControl) 
[18, 27] and then labeled with BrdU. Knockdown of EphA2 by shRNA 
significantly suppressed EGF-stimulated BrdU incorporation (Fig. 2C). We 
could not detect apoptosis in U-251 cells transfected with EphA2 shRNA 
(Fig. 2D). Taken together, these results suggest that EphA2 is required for 
the EGF-stimulated cell proliferation in U-251 cells.  
To examine whether the involvement of EphA2 in EGF-induced 
promotion of cell proliferation is limited to U-251 cells, we used another 
glioblastoma cell line A172. A172 cells express similar endogenous level of 
EphA2 to U-251, and expression of EphA2 was down-regulated after long 
exposure to ephrinA1-Fc (Fig. 2E). Stimulation of A172 cells with EGF 
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increased the number of BrdU-positive cells, and ephrinA1 treatment 
significantly suppressed EGF-induced BrdU incorporation (Fig. 2F). Thus, 
the regulation of glioblastoma cell proliferation by EphA2 in response to 
EGF stimulation is not specific to U-251 cells. 
 
3.2. EGF induces phosphorylation of EphA2 on S897 through the 
MEK/ERK/RSK pathway 
Phosphorylation of EphA2 on S897 by Akt plays a key role in 
EphA2 ligand-independent glioblastoma cell migration and invasion [17, 
19, 23]. Therefore, we next examined whether EphA2 is phosphorylated on 
S897 in response to EGF stimulation in U-251 cells using an antibody 
against S897-phosphorylated EphA2 (pS897-EphA2). We found that EGF 
stimulation resulted in marked phosphorylation of S897 EphA2. However, 
Akt inhibitor MK-2206 and its upstream PI3K inhibitor LY294002 had no 
effect on EGF-induced EphA2 phosphorylation on S897 (Fig. 3A). On the 
other hand, EGF-induced EphA2 S897 phosphorylation was completely 
suppressed by MEK inhibitors U0126 and PD980759 (Fig. 3B), suggesting 
that phosphorylation of EphA2 on S897 in U-251 cells occurs downstream 
of the MEK/ERK pathway. RSK is a downstream target of ERK [4, 5], and 
phosphorylation sites in many known substrates of Akt and RSK are similar 
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[32]. Therefore, we speculated that RSK is a candidate of kinases that 
induce EphA2 S897 phosphorylation. Our result showed that treatment of 
U-251 cells with RSK inhibitor BI-D1870 suppressed EGF-induced 
phosphorylation of EphA2 on S897 (Fig. 3C). To examine whether 
overexpression of RSK alone induces EphA2 S897 phosphorylation, we 
constructed HA-tagged wild-type RSK2, because U-251 cells express 
RSK2 among RSK members (data not shown). HEK293T cells were 
transfected with wild-type EphA2 (EphA2-WT) or S897A mutant 
(EphA2-SA) together with HA-RSK2, and the cell lysates were 
immunoblotted with anti-pS897-EphA2 antibody. Overexpression of 
EphA2-WT alone resulted in S897 phosphorylation, and it was enhanced 
by co-expression with RSK2. However, S897 phosphorylation was not 
detected in cells transfected with EphA2-SA and RSK2 (Fig. 3D). We also 
found that stimulation of A172 cells with EGF induced phosphorylation of 
S897 EphA2, and this phosphorylation was suppressed by BI-D1870 and 
U0126, but not by MK-2206 and LY294002 (Fig. 3E and F). These results 
suggest that EGF induces phosphorylation of EphA2 on S897 through the 
MEK/ERK/RSK pathway in glioblastoma cells. 
 
3.4. EphA2 S897 Phosphorylation is required for the EGF-induced 
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promotion of cell proliferation 
To examine whether EphA2 S897 phosphorylation by RSK is 
required for EGF-induced cell proliferation, we first examined the effect of 
RSK inhibitor BI-D1870 on EGF-stimulated BrdU incorporation in U-251 
cells. We found that treatment of the cells with BI-D1870 significantly 
suppressed EGF-induced BrdU incorporation (Fig. 4A). Although RSK 
inhibition has been reported to induce apoptosis in other cancer cell types 
[33, 34], we could not detect apoptosis in U-251 cells under these 
conditions (Fig. 4B). To confirm the involvement of RSK in EGF-induced 
cell proliferation, we constructed an shRNA vector against human RSK2 
(shRSK2), which effectively reduced the amount of exogenously expressed 
HA-RSK2 in HEK293T cells (Fig. 4C). U-251 cells were transfected with 
shRSK2 or shControl and labeled with BrdU. Knockdown of RSK2 by 
shRNA significantly suppressed EGF-stimulated BrdU incorporation (Fig. 
4D). These results suggest that RSK2 is involved in EGF-induced cell 
proliferation. The RSK inhibitor also significantly suppressed EGF-induced 
promotion of BrdU incorporation in A172 cells (Fig. 4E).  
We next transfected U-251 cells with EphA2-WT or EphA2-SA 
together with GFP for BrdU incorporation, and measured the number of 
BrdU-labeled GFP-positive cells in the total number of GFP-positive cells. 
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Overexpression of GFP alone had little effect on the EGF-induced 
promotion of BrdU incorporation. However, overexpression of EphA2-WT 
induced a significant increase in the number of BrdU-positive cells without 
EGF stimulation (Fig. 5A). In contrast, expression of EphA2-SA 
suppressed the EGF-induced promotion of BrdU incorporation. The 
immunofluorescence staining with anti-EphA2 antibody confirmed the 
expression of EphA2-WT or EphA2-SA in GFP-expressing cells (Fig. 5B). 
We also found that treatment of the cells with the RSK inhibitor BI-D1870 
significantly suppressed EphA2-WT-induced BrdU incorporation (Fig. 5C). 
On the other hand, overexpression of RSK2 induced promotion of BrdU 
incorporation without EGF stimulation, and this was suppressed by 
co-expression with EphA2-SA (Fig. 5D). These results suggest that 
phosphorylation of EphA2 on S897 by RSK promotes cell proliferation. 
 
4. Discussion 
EphA2 is frequently overexpressed in glioblastoma and its 
expression level correlates with poor prognosis of patients. On the other 
hand, abnormal EGF receptor signaling is one of major factors for 
oncogenic progression of glioblastoma. However, the relationship between 
EGF receptor and EphA2 remains unknown. In this study, we show that 
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EphA2 plays a key role in EGF-stimulated glioblastoma cell proliferation 
through a ligand ephrin-independent manner. Previous studies reported that 
ligand-independent EphA2 S897 phosphorylation by Akt promotes 
glioblastoma cell migration and invasion. However, we found that 
stimulation of U-251 and A172 glioblastoma cells with EGF triggers 
phosphorylation of EphA2 on S897 through the MEK/ERK/RSK pathway 
and promotes cell proliferation. Thus, our results uncover a novel 
mechanism that regulates glioblastoma cell proliferation, and RSK is a key 
mediator of EGF receptor signaling to EphA2 in oncogenic responses.  
Previous studies reported that Akt phosphorylates S897 of EphA2 in 
response to several growth factors and promotes cell migration and 
invasion [17, 19-21]. Phosphorylation of EphA2 by Akt also regulates stem 
cell like properties in glioma [23]. However, our data show that EphA2 
phosphorylation on S897 in response to EGF stimulation is suppressed by 
MEK and RSK inhibitors, but not by PI3K and Akt inhibitors in 
glioblastoma cells. In addition, U-251 and A172 are PTEN-deficient cell 
lines, and Akt activity (T308 phosphorylation) is observed without growth 
factor stimulation in those cells. However, the basal level of EphA2 S897 
phosphorylation is undetectable, and it is up-regulated by EGF stimulation. 
This result also supports our conclusion that Akt is not responsible for 
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phosphorylating S897 EphA2 in U-251 and A172 cells. Akt and RSK 
phosphorylate many known substrates at a similar motif [32]. In addition, 
Zhou et al. recently demonstrated that MEK and RSK inhibitors can block 
EphA2 S897 phosphorylation in many cancer cell types, and that RSK can 
directly phosphorylates S897 of EphA2 [25]. On the other hand, we 
recently reported that stimulation of MDCK cells with hepatocyte growth 
factor in three-dimensional culture phosphorylates S897 of EphA2 through 
the PI3K/Akt pathway and regulates epithelial morphogenesis [24]. 
Therefore, EphA2 phosphorylation on S897 by RSK or Akt may depend on 
the cellular context and/or functions.  
Although genes of RSK family are not frequently mutated or 
amplified in malignant tumors, RSK is implicated in the regulation of 
cancer cell invasion and metastasis [7]. Among RSK family members, 
RSK1 and RSK2 have been reported to show promotion of cancer cell 
motility in various cancer cell types, including head and neck squamous 
cell carcinoma, colon adenocarcinoma, and prostate cancer cell lines, 
through cancer-specific mechanisms [35-37]. On the other hand, RSK1 and 
RSK2 promote proliferation of prostate and breast cancer cells [38, 39]. 
RSKs are known to phosphorylate several transcription factors and the cell 
cycle machinery, including c-Fos, p27kip1, and Cdc25 [4-6]. In glioblastoma, 
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however, the roles of RSKs in cancer progression still remain unclear. In 
this study, we provide evidence that RSK is involved in cell proliferation in 
U-251 and A172 glioblastoma cells through phosphorylation of EphA2. 
Thus, our results suggest that EphA2 is one of key RSK substrates in the 
regulation of cancer cell proliferation. EphA2 phosphorylated on S897 also 
promotes cell migration and invasion in various types of cancer cells [17, 
19-21, 23, 25]. Therefore, RSK may also regulate migration and invasion 
of glioblastoma cells by phosphorylating S897 of EphA2.  
The mechanism by which ligand-independent EphA2 signaling 
promotes glioblastoma cell proliferation is unclear. In cholangiocarcinoma 
cells, overexpression of EphA2 has been reported to activate the mTORC1 
pathway through a ligand-independent manner [40]. Therefore, we 
examined the involvement of EphA2 in the regulation of mTORC1 activity, 
which positively regulates cell proliferation in many cell types. However, 
both downregulation of EphA2 and treatment with the RSK inhibitor had 
little effect on the phosphorylation state of mTORC1 substrate ribosomal 
S6 kinase in response to EGF stimulation (data not shown). Further studies 
are required to elucidate how ligand-independent EphA2 signaling 




In this study, we demonstrate a molecular link between EGF receptor 
and EphA2 in the regulation of glioblastoma cell proliferation. EGF 
stimulation results in phosphorylation of S897 EphA2 through the 
MEK/ERK/RSK pathway, leading to promotion of cell proliferation. On 
the basis of these findings, we propose that understanding the mechanism 
underlying the RSK-EphA2 axis may reveal new targets for EGF 
receptor-targeted brain cancer therapy.  
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Fig. 1. EphA2 is involved in EGF-induced cell proliferation in U-251 cells. 
A. U-251 cells were treated with control-Fc or ephrinA1-Fc (1 µg/ml) for 
indicated times, and the cell lysates were analyzed by immunoblotting with 
antibodies against EphA2 and a-tubulin. B. U-251 cells were treated with 
control-Fc or ephrinA1-Fc (1 µg/ml) and stimulated with EGF (100 ng/ml) 
for 48 h. Scale bar, 100 µm. C. Cell proliferation was assessed by 
measuring MTT absorbance at 0 h and 48 h, and relative proliferation of 
cells were expressed as fold change in MTT absorbance relative to that at 0 
h. Data are the means ± SEM of five independent experiments (**p < 0.01, 
one-way ANOVA, Bonferroni, EGF + control-Fc vs. EGF + ephrinA1-Fc). 
D. U-251 cells were treated with control-Fc or ephrinA1-Fc (1 µg/ml) and 
stimulated with EGF (100 ng/ml) for 48 h. As a positive control, U-251 
cells were treated with 1 mM H2O2 for 24 h. Apoptotic cells were detected 
by TUNEL assay. Scale bar, 100 µm.   
 
Fig. 2. EphA2 mediates EGF-stimulated BrdU incorporation. A. U-251 
cells were treated with control-Fc or ephrinA1-Fc (1 µg/ml) together with 
EGF (100 ng/ml) for 20 h and labeled with BrdU (10 µM) for 30 min. Then 
cells were stained with anti-BrdU antibody and Hoechst 33258. Scale bar, 
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50 µm. B. The number of BrdU-positive cells was counted, and the 
percentage of BrdU-positive cells in the total cell number was shown. Data 
are the means ± SEM of four independent experiments (***p < 0.001, 
one-way ANOVA, Bonferroni). C. U-251 cells transfected with shControl 
or shEphA2 were treated with EGF (100 ng/ml) for 20 h and labeled with 
BrdU for 30 min. Then cells were stained with anti-BrdU and anti-GFP 
antibodies. The number of BrdU-positive and/or GFP-positive cells was 
counted, and the percentage of BrdU-labeled GFP-positive cells in the total 
number of GFP-positive cells (BrdU+GFP+/GFP+) was shown. Data are 
the means ± SEM of three independent experiments (*p < 0.05, one-way 
ANOVA, Bonferroni). D. U-251 cells were transfected with shControl or 
shEphA2, and apoptotic cells were detected by TUNEL assay. Scale bar, 50 
µm. E. A172 cells were treated with control-Fc or ephrinA1-Fc (1 µg/ml) 
for 24 h, and the cell lysates were analyzed by immunoblotting with 
antibodies against EphA2 and a-tubulin. F. A172 cells were treated with 
control-Fc or ephrinA1-Fc (1 µg/ml) together with EGF (100 ng/ml) for 24 
h and labeled with BrdU (10 µM) for 6 h. Then cells were stained with 
anti-BrdU antibody and Hoechst 33258. The number of BrdU-positive cells 
was counted, and the percentage of BrdU-positive cells in the total cell 
number was shown. Data are the means ± SEM of three independent 
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experiments (*p < 0.05, one-way ANOVA, Bonferroni). 
 
Fig. 3. EGF induces EphA2 phosphorylation on S897 through the 
MEK/ERK/RSK pathway. A. U-251 cells were treated with MK2206 (1 
µM) or LY294002 (20 µM) for 30 min and then stimulated with EGF (100 
ng/ml) for 10 min. Cell lysates were analyzed by immunoblotting with the 
indicated antibodies. B. U-251 cells were treated with U0126 (20 µM) or 
PD98059 (20 µM) for 30 min and then stimulated with EGF (100 ng/ml) 
for 10 min. C. U-251 cells were treated with BI–D1870 (10 µM) or U0126 
(20 µM) for 30 min and then stimulated with EGF (100 ng/ml) for 10 min. 
D. Cell lysates from HEK293T cells transfected with the indicated 
plasmids were immunoblotted with the indicated antibodies. E. A172 cells 
were treated with BI–D1870 (10 µM) or U0126 (20 µM) for 30 min and 
then stimulated with EGF (100 ng/ml) for 10 min. F. A172 cells were 
treated with MK2206 (1 µM) or LY294002 (20 µM) for 30 min and then 
stimulated with EGF (100 ng/ml) for 10 min. Cell lysates were analyzed by 
immunoblotting with the indicated antibodies. 
 
Fig. 4. RSK is involved in the EGF-induced promotion of cell proliferation. 
A. U-251 cells were treated with BI-D1870 (10 µM) for 30 min, and then 
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EGF (100 ng/ml) was added for 20 h. Cells were then labeled with BrdU 
for 30 min and stained with anti-BrdU antibody and Hoechst 33258. The 
number of BrdU-positive cells was counted, and the percentage of 
BrdU-positive cells in the total cell number was shown. Data are the means 
± SEM of four independent experiments (*p < 0.05, student’s t test). B. 
U-251 cells were treated with BI-D1870 for 30 min and stimulated with 
EGF (100 ng/ml) for 20 h. Apoptotic cells were detected by TUNEL assay. 
Scale bar, 100 µm. C. Cell lysates from HEK293T cells transiently 
transfected with shControl or shRSK2 were analyzed by immunoblotting 
with antibodies against HA and a-tubulin. D. U-251 cells transfected with 
shControl or shRSK2 were treated with EGF (100 ng/ml) for 24 h and 
labeled with BrdU for 30 min. Then cells were stained with anti-BrdU and 
anti-GFP antibodies. The number of BrdU-positive and/or GFP-positive 
cells was counted, and the percentage of BrdU-labeled GFP-positive cells 
in the total number of GFP-positive cells (BrdU+GFP+/GFP+) was shown. 
Data are the means ± SEM of three independent experiments (*p < 0.05, 
**p < 0.01, one-way ANOVA, Bonferroni). E. A172 cells were treated with 
BI-D1870 (10 µM) for 30 min, and then EGF (100 ng/ml) was added for 24 
h. Cells were then labeled with BrdU for 6 h and stained with anti-BrdU 
antibody and Hoechst 33258. The number of BrdU-positive cells was 
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counted, and the percentage of BrdU-positive cells in the total cell number 
was shown. Data are the means ± SEM of six independent experiments (*p 
< 0.05, student’s t test). 
 
Fig. 5. EphA2 S897 phosphorylation is required for the EGF-induced cell 
proliferation. A. U-251 cells were transfected with GFP and the indicated 
plasmids and treated with EGF (100 ng/ml) for 20 h. Then cells were 
stained with anti-BrdU and anti-GFP antibodies. The number of 
BrdU-positive and/or GFP-positive cells was counted, and the percentage 
of BrdU-labeled GFP-positive cells in the total number of GFP-positive 
cells (BrdU+GFP+/GFP+) was shown. Data are the means ± SEM of four 
independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, one-way 
ANOVA, Bonferroni). B. U-251 cells transfected with GFP and the 
indicated plasmids were stained with anti-EphA2 antibody. Scale bar, 50 
µm. C. U-251 cells transfected with GFP and EphA2-WT were treated with 
BI-D1870 for 20 h. Then cells were stained with anti-BrdU and anti-GFP 
antibodies. The number of BrdU-positive and/or GFP-positive cells was 
counted, and the percentage of BrdU-labeled GFP-positive cells in the total 
number of GFP-positive cells (BrdU+GFP+/GFP+) was shown. Data are 
the means ± SEM of five independent experiments (**p < 0.01, one-way 
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ANOVA, Bonferroni). D. U-251 cells were transfected with GFP and the 
indicated plasmids, and were stained with anti-BrdU and anti-GFP 
antibodies. The number of BrdU-positive and/or GFP-positive cells was 
counted, and the percentage of BrdU-labeled GFP-positive cells in the total 
number of GFP-positive cells (BrdU+GFP+/GFP+) was shown. Data are 
the means ± SEM of four independent experiments (**p < 0.01, one-way 
ANOVA, Bonferroni). 
 
 





